Sera Prognostics - רווח נקי למניה בארבעת הרבעונים האחרונים SERA

Sera Prognostics implements advanced AI solutions and proteomics for pregnancy risk analysis, possessing colossal scientific potential. Serving as a valuation tool, the EPS (TTM) chart shows a value of 13.40. Business development relies on a team of outstanding biologists motivated by the opportunity to save infants through high-precision diagnostics, which guarantees exceptional loyalty among the company's key employees.

Sera Prognostics maintains a niche in high-tech diagnostics, yet reliance on external IT hosting and logistics creates risks of rising costs. This indicator measures the rate of change in earnings per share over twelve months, reflecting the efficiency of capital management. By analyzing the percentage change in trailing twelve-month EPS, an investor determines the business's ability to offset outsourcing expenses. Steady growth in this metric confirms the long-term sustainability of the business model.